Hypokalaemia · preterm infants (< 37 weeks GA) at risk of chronic lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease
1 finding from 1 review
Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
Continuous abstinence from cocaine (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) · patients with the treatment of cocaine dependence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Point abstinence (number of participants who were abstinent at the end of the treatment) · patients with the treatment of cocaine dependence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes dropout for any reason (number of participants who did not complete… compared with naltrexone (very low certainty).
1 finding from 1 review
Dropouts due to adverse events · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes dropout due to adverse events (number of participants who did not… compared with naltrexone (very low certainty).
1 finding from 1 review
RR 0.5 [0.07, 3.55]
1 study · 8 participants
Very low
Adverse events as N of participants with at least one adverse event objective · patients with the treatment of cocaine dependence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
Continuous abstinence from cocaine (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) · patients with the treatment of cocaine dependence
Summary of findings table – disulfiram showed no clear difference in continuous abstinence from cocaine (number of participants who had… compared with placebo or no pharmacological treatment (low certainty).
1 finding from 1 review
Point abstinence (number of participants who were abstinent at the end of the treatment) · patients with the treatment of cocaine dependence
Summary of findings table – disulfiram may leads to higher point abstinence (number of participants who were abstinent at the… compared with placebo or no pharmacological treatment (low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · patients with the treatment of cocaine dependence
Summary of findings table – disulfiram showed no clear difference in dropout for any reason (number of participants who did not complete… compared with placebo or no pharmacological treatment (low certainty).
1 finding from 1 review
Dropouts due to adverse events · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes dropout due to adverse events (number of participants who did not… compared with placebo or no pharmacological treatment (very low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes any adverse events (number of participants who experienced at least… compared with placebo or no pharmacological treatment (very low certainty).
1 finding from 1 review
Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Gabapentin changes risk for at least one adverse event per patient compared with pregabalin (very low certainty).
1 finding from 1 review
PruritusScale from: 0 to 10 · participants with cholestatic pruritus (CP)
1 finding from 1 review
Quality of life ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found